{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:52:28Z","timestamp":1793865148985,"version":"4.6.1"},"reference-count":171,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The National Cancer Center Research and Development Fund","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Given the low incidence, variety of histological types, and heterogeneous biological features of head and neck sarcomas, there is limited high-quality evidence available to head and neck oncologists. For resectable sarcomas, surgical resection followed by radiotherapy is the principle of local treatment, and perioperative chemotherapy is considered for chemotherapy-sensitive sarcomas. They often originate in anatomical border areas such as the skull base and mediastinum, and they require a multidisciplinary treatment approach considering functional and cosmetic impairment. Moreover, head and neck sarcomas may exhibit different behaviour and characteristics than sarcomas of other areas. In recent years, the molecular biological features of sarcomas have been used for the pathological diagnosis and development of novel agents. This review describes the historical background and recent topics that head and neck oncologists should know about this rare tumour from the following five perspectives: (i) epidemiology and general characteristics of head and neck sarcomas; (ii) changes in histopathological diagnosis in the genomic era; (iii) current standard treatment by histological type and clinical questions specific to head and neck; (iv) new drugs for advanced and metastatic soft tissue sarcomas; and (v) proton and carbon ion radiotherapy for head and neck sarcomas.<\/jats:p>","DOI":"10.1093\/jjco\/hyad048","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T07:02:45Z","timestamp":1686639765000},"page":"743-756","source":"Crossref","is-referenced-by-count":16,"title":["Current topics and management of head and neck sarcomas"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5823-3718","authenticated-orcid":false,"given":"Kenya","family":"Kobayashi","sequence":"first","affiliation":[{"name":"University of Tokyo Department of Otolaryngology\u2013Head and Neck Surgery, , Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Hanai","sequence":"additional","affiliation":[{"name":"Aichi Cancer Center Hospital Department of Head and Neck Surgery, , Nagoya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-095X","authenticated-orcid":false,"given":"Seiichi","family":"Yoshimoto","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, National Cancer Center Hospital, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Saito","sequence":"additional","affiliation":[{"name":"University of Tokyo Department of Otolaryngology\u2013Head and Neck Surgery, , Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Homma","sequence":"additional","affiliation":[{"name":"Hokkaido University Department of Otolaryngology\u2013Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, , Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,10]]},"reference":[{"key":"2023092723195024700_ref1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11912-002-0050-y","article-title":"Sarcomas of the head and neck","volume":"4","author":"Kraus","year":"2002","journal-title":"Curr Oncol Rep"},{"key":"2023092723195024700_ref2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1097-0142(19940715)74:2<697::AID-CNCR2820740224>3.0.CO;2-A","article-title":"Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas","volume":"74","author":"Kraus","year":"1994","journal-title":"Cancer"},{"key":"2023092723195024700_ref3","volume-title":"Principles and practice of head and neck surgery and oncology","author":"Montogomery","year":"2009","edition":"2nd"},{"key":"2023092723195024700_ref4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13577140020008066","article-title":"Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline","volume":"4","author":"Bramwell","year":"2000","journal-title":"Sarcoma"},{"key":"2023092723195024700_ref5","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Graaf","year":"2012","journal-title":"Lancet"},{"key":"2023092723195024700_ref6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref7","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"key":"2023092723195024700_ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hed.2880140102","article-title":"Head and neck sarcoma: report of the Head and Neck Sarcoma Registry. Society of Head and Neck Surgeons Committee on Research","volume":"14","author":"Wanebo","year":"1992","journal-title":"Head Neck"},{"key":"2023092723195024700_ref9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0748-7983(95)91558-3","article-title":"Report of a symposium on diagnosis and treatment of adult soft tissue sarcomas in the head and neck","volume":"21","author":"Balm","year":"1995","journal-title":"Eur J Surg Oncol"},{"key":"2023092723195024700_ref10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<193::AID-CNCR31>3.0.CO;2-Z","article-title":"Soft tissue sarcoma of the head and neck in children and adolescents","volume":"77","author":"Lyos","year":"1996","journal-title":"Cancer"},{"key":"2023092723195024700_ref11","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/0194599814545747","article-title":"Head and neck sarcomas: analysis of the SEER database","volume":"151","author":"Peng","year":"2014","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2023092723195024700_ref12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00000478-199002000-00005","article-title":"A clinicopathologic study of 10 cases with a comparison to soft-tissue counterparts","volume":"14","author":"Wenig","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"2023092723195024700_ref13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/1097-0142(19950915)76:6<1051::AID-CNCR2820760620>3.0.CO;2-4","article-title":"Head and neck liposarcoma","volume":"76","author":"Golledge","year":"1995","journal-title":"Cancer"},{"key":"2023092723195024700_ref14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/modpathol.3880526","article-title":"Distinctive soft tissue tumors of the head and neck","volume":"15","author":"Fletcher","year":"2002","journal-title":"Mod Pathol"},{"key":"2023092723195024700_ref15","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1245\/ASO.2004.04.027","article-title":"Prognosis of lymph node metastasis in soft tissue sarcoma","volume":"11","author":"Behranwala","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"2023092723195024700_ref16","first-page":"1670","article-title":"Risk factors for lymph node metastasis of soft tissue sarcomas of the head, neck, and extremities, and the clinical significance of negative lymph node dissection","volume":"98","author":"Liu","year":"2022","journal-title":"J Orthop Surg Res"},{"key":"2023092723195024700_ref17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejso.2017.11.014","article-title":"Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma","volume":"44","author":"Keung","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"2023092723195024700_ref18","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s11999-012-2568-0","article-title":"Lymphadenectomy and histologic subtype affect overall survival of soft tissue sarcoma patients with nodal metastases","volume":"471","author":"Aswamura","year":"2013","journal-title":"Clin Orthop Relat Res"},{"key":"2023092723195024700_ref19","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/cncr.11716","article-title":"National Cancer Data Base report on osteosarcoma of the head and neck","volume":"98","author":"Smith","year":"2003","journal-title":"Cancer"},{"key":"2023092723195024700_ref20","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2106\/00004623-199605000-00003","article-title":"Residual disease following unplanned excision of soft-tissue sarcoma of an extremity","volume":"78","author":"Noria","year":"1996","journal-title":"J Bone Joint Surg Am"},{"key":"2023092723195024700_ref21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/13854","article-title":"Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein","volume":"23","author":"Hahm","year":"1999","journal-title":"Nat Genet"},{"key":"2023092723195024700_ref22","doi-asserted-by":"crossref","first-page":"1700130","DOI":"10.1002\/prca.201700130","article-title":"Current status of proteomics in Ewing\u2019s sarcoma","volume":"13","author":"Kondo","year":"2019","journal-title":"Proteomics Clin Appl"},{"key":"2023092723195024700_ref23","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/363640a0","article-title":"Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma","volume":"363","author":"Crozat","year":"1993","journal-title":"Nature"},{"key":"2023092723195024700_ref24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/sj.onc.1202346","article-title":"Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas","volume":"18","author":"Wunder","year":"1999","journal-title":"Oncogene"},{"key":"2023092723195024700_ref25","doi-asserted-by":"crossref","first-page":"18085","DOI":"10.1073\/pnas.0708910104","article-title":"PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1","volume":"104","author":"Roeb","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"2023092723195024700_ref26","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cncr.32735","article-title":"Core needle biopsy versus incisional biopsy for differentiation of soft-tissue sarcomas: a systematic review and meta-analysis","volume":"126","author":"Birgin","year":"2020","journal-title":"Cancer"},{"key":"2023092723195024700_ref27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jso.20504","article-title":"Accurate diagnosis of musculoskeletal lesions by core needle biopsy","volume":"94","author":"Mitsuyoshi","year":"2006","journal-title":"J Surg Oncol"},{"key":"2023092723195024700_ref28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.21037\/cco.2018.10.09","article-title":"Who, how and what of pathology of soft tissue sarcoma","volume":"10","author":"Renne","year":"2021","journal-title":"Chin Clin Oncol"},{"key":"2023092723195024700_ref29","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/cncr.30370","article-title":"Needle tract seeding after percutaneous biopsy of sarcoma: risk\/benefit considerations","volume":"123","author":"Berger-Richardson","year":"2017","journal-title":"Cancer"},{"key":"2023092723195024700_ref30","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/hed.26670","article-title":"Diagnostic use of fine-needle aspiration cytology and core-needle biopsy in head and neck sarcomas","volume":"43","author":"Sheppard","year":"2021","journal-title":"Head Neck"},{"key":"2023092723195024700_ref31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2559.2005.02288.x","article-title":"Grading of soft tissue sarcomas: the challenge of providing precise information in an imprecise world","volume":"48","author":"Deyrup","year":"2006","journal-title":"Histopathology"},{"key":"2023092723195024700_ref32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/cncr.11550","article-title":"Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution","volume":"98","author":"Ferrari","year":"2003","journal-title":"Cancer"},{"key":"2023092723195024700_ref33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/1097-0142(19880115)61:2<209::AID-CNCR2820610202>3.0.CO;2-L","article-title":"The Intergroup Rhabdomyosarcoma Study-I. A final report","volume":"61","author":"Maurer","year":"1988","journal-title":"Cancer"},{"key":"2023092723195024700_ref34","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/1097-0142(19930301)71:5<1904::AID-CNCR2820710530>3.0.CO;2-X","article-title":"The Intergroup Rhabdomyosarcoma Study-II","volume":"71","author":"Maurer","year":"1993","journal-title":"Cancer"},{"key":"2023092723195024700_ref35","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.1995.13.3.610","article-title":"The third intergroup rhabdomyosarcoma study","volume":"13","author":"Crist","year":"1995","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref36","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2001.19.12.3091","article-title":"Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease","volume":"19","author":"Crist","year":"2001","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref37","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1200\/JCO.1995.13.8.2123","article-title":"Biology and therapy of pediatric rhabdomyosarcoma","volume":"13","author":"Pappo","year":"1995","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref38","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.2010.30.4469","article-title":"Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children\u2019s Oncology Group","volume":"29","author":"Beverly Raney","year":"2011","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref39","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1200\/JCO.2009.22.3768","article-title":"Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children\u2019s Oncology Group Study D9803","volume":"27","author":"Arndt","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2006.07.1720","article-title":"Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children\u2019s Oncology Group","volume":"25","author":"Pappo","year":"2007","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref41","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/(SICI)1097-0142(19970915)80:6<1165::AID-CNCR21>3.0.CO;2-5","article-title":"Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children\u2019s Cancer Study Group. Pediatric Oncology Group","volume":"80","author":"Lawrence","year":"1997","journal-title":"Cancer"},{"key":"2023092723195024700_ref42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ped.12867","article-title":"Current status of treatment for pediatric rhabdomyosarcoma in the USA and Japan","volume":"58","author":"Hosoi","year":"2016","journal-title":"Pediatr Int"},{"key":"2023092723195024700_ref43","volume-title":"Pediatr Blood Cancer","author":"Suman Malempati"},{"key":"2023092723195024700_ref44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2021.04.007","article-title":"Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) - RMS2005 study","volume":"151","author":"Glosli","year":"2021","journal-title":"Eur J Cancer"},{"key":"2023092723195024700_ref45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2020.12.025","article-title":"Embryonal rhabdomyosarcoma completely resected at diagnosis: the European Paediatric Soft Tissue Sarcoma Study Group RMS2005 experience","volume":"146","author":"Bergeron","year":"2021","journal-title":"Eur J Cancer"},{"key":"2023092723195024700_ref46","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(18)30337-1","article-title":"Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial","volume":"19","author":"Bisogno","year":"2018","journal-title":"Lancet Oncol"},{"key":"2023092723195024700_ref47","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1172\/JCI117344","article-title":"Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma","volume":"94","author":"Zhan","year":"1994","journal-title":"J Clin Invest"},{"key":"2023092723195024700_ref48","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/path.2499","article-title":"The insulin-like growth factor system and sarcomas","volume":"217","author":"Rikhof","year":"2009","journal-title":"J Pathol"},{"key":"2023092723195024700_ref49","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/pbc.24532","article-title":"PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a Children\u2019s Oncology Group report","volume":"60","author":"Skapek","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2023092723195024700_ref50","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2011.38.5591","article-title":"PAX3\/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification","volume":"30","author":"Missiaglia","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/1097-0142(19870101)59:1<147::AID-CNCR2820590129>3.0.CO;2-8","article-title":"Improved prognosis with intensive treatment of children with cranial soft tissue sarcomas arising in nonorbital parameningeal sites. A report from the Intergroup Rhabdomyosarcoma Study","volume":"59","author":"Raney","year":"1987","journal-title":"Cancer"},{"key":"2023092723195024700_ref52","doi-asserted-by":"crossref","first-page":"e29751","DOI":"10.1002\/pbc.29751","article-title":"Local control of parameningeal rhabdomyosarcoma: an expert consensus guideline from the International Soft Tissue Sarcoma Consortium (INSTRuCT)","volume":"69","author":"Casey","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"2023092723195024700_ref53","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/archotol.126.4.468","article-title":"Pediatric rhabdomyosarcoma of the head and neck: is there a place for surgical management?","volume":"126","author":"Daya","year":"2000","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2023092723195024700_ref54","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1055\/s-0036-1597279","article-title":"Minimally invasive approach for resection of parameningeal rhabdomyosarcoma","volume":"78","author":"Wertz","year":"2017","journal-title":"J Neurol Surg B Skull Base"},{"issue":"Suppl. 1","key":"2023092723195024700_ref55","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/SCS.0b013e31819280ed","article-title":"Reconstruction of pediatric cranial base defects: a review of a single microsurgeon\u2019s 30-year experience","volume":"20","author":"Carty","year":"2009","journal-title":"J Craniofac Surg"},{"key":"2023092723195024700_ref56","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0037-1615816","article-title":"Impact of surgical margin in skull base surgery for head and neck sarcomas","volume":"79","author":"Kobayashi","year":"2018","journal-title":"J Neurol Surg B Skull Base"},{"key":"2023092723195024700_ref57","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1002\/cam4.855","article-title":"Significance of delayed primary excision in localized nonmetastatic adult head and neck rhabdomyosarcoma","volume":"5","author":"Kobayashi","year":"2016","journal-title":"Cancer Med"},{"key":"2023092723195024700_ref58","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1055\/s-0041-1736590","article-title":"Surgical management of rhabdomyosarcoma of the nasal cavity and paranasal sinuses: analysis of operative indications, settings, and outcomes","volume":"83","author":"Kana","year":"2022","journal-title":"J Neurol Surg B Skull Base"},{"key":"2023092723195024700_ref59","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/pbc.24289","article-title":"Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols-III and -IV, 1984\u20131997: a report from the Children\u2019s Oncology Group","volume":"60","author":"Raney","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2023092723195024700_ref60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/(SICI)1096-911X(199707)29:1<51::AID-MPO10>3.0.CO;2-7","article-title":"Orbital rhadbomyosarcomas and related tumors in childhood: relationship of morphology to prognosis\u2014an intergroup rhabdomyosarcoma study","volume":"29","author":"Kodet","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"2023092723195024700_ref61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(05)01733-X","article-title":"Treatment for childhood rhabdomyosarcoma: the cost of cure","volume":"6","author":"Stevens","year":"2005","journal-title":"Lancet Oncol"},{"key":"2023092723195024700_ref62","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"key":"2023092723195024700_ref63","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/pbc.20310","article-title":"Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study","volume":"44","author":"Punyko","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"2023092723195024700_ref64","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ijc.29351","article-title":"Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children\u2019s Oncology Group Soft Tissue Sarcoma Committee","volume":"137","author":"Rodeberg","year":"2015","journal-title":"Int J Cancer"},{"key":"2023092723195024700_ref65","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/(SICI)1096-911X(199910)33:4<362::AID-MPO4>3.0.CO;2-I","article-title":"Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: a descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and -III. IRS group of the Children\u2019s Cancer Group and the Pediatric Oncology Group","volume":"33","author":"Raney","year":"1999","journal-title":"Med Pediatr Oncol"},{"key":"2023092723195024700_ref66","doi-asserted-by":"crossref","first-page":"105145","DOI":"10.1016\/j.oraloncology.2020.105145","article-title":"Head and neck tumors in children and adolescents: impact of a multidisciplinary tumor board","volume":"114","author":"Benoit","year":"2021","journal-title":"Oral Oncol"},{"key":"2023092723195024700_ref67","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/cncr.33275","article-title":"Benefit of delayed primary excision in rhabdomyosarcoma: a report from the Children\u2019s Oncology Group","volume":"127","author":"Lautz","year":"2021","journal-title":"Cancer"},{"key":"2023092723195024700_ref68","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.2015.63.4048","article-title":"Intensive multiagent therapy, including dose-compressed cycles of ifosfamide\/etoposide and vincristine\/doxorubicin\/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: a report from the Children\u2019s Oncology Group","volume":"34","author":"Weigel","year":"2016","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref69","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/pbc.20227","article-title":"Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent\/refractory sarcoma: the Children\u2019s Cancer Group (CCG) experience","volume":"44","author":"Van Winkle","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"2023092723195024700_ref70","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/cncr.20544","article-title":"Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcomas Protocol","volume":"101","author":"Casanova","year":"2004","journal-title":"Cancer"},{"key":"2023092723195024700_ref71","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.ejca.2012.04.012","article-title":"Phase II study of vinorelbine and continuous low dose cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumor: good tolerance profile and efficacy in rhabdomyosarcoma\u2014a report from the Societe Francaise des Cancers et leucemies de i\u2019Enfant et de i\u2019adolescent (SFCE)","volume":"48","author":"Minard-Colin","year":"2012","journal-title":"Eur J Cancer"},{"key":"2023092723195024700_ref72","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1200\/JCO.2010.29.7390","article-title":"Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children\u2019s Oncology Group","volume":"28","author":"Mascarenhas","year":"2010","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref73","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1200\/JCO.21.00124","article-title":"Randomized Phase II trial of vincristine-irinotecan with or without temozolomide, in children and adults with relapsed or refractory rhabdomyosarcoma: A European Pediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children with Cancer Trial","volume":"39","author":"Defachelles","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref74","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.amjoto.2010.09.002","article-title":"Head and neck osteosarcoma","volume":"32","author":"Mendenhall","year":"2011","journal-title":"Am J Otolaryngol"},{"key":"2023092723195024700_ref75","volume-title":"Soft tissue and bone tumors (ed by WHO Classification of Tumors editorial board)","author":"WHO Classification of Tumor","year":"2020","edition":"5th"},{"key":"2023092723195024700_ref76","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2106\/00004623-199403000-00007","article-title":"Parosteal osteosarcoma. A clinicopathological study","volume":"76","author":"Okada","year":"1994","journal-title":"J Bone Joint Surg Am"},{"key":"2023092723195024700_ref77","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/01.blo.0000229341.18974.95","article-title":"Periosteal osteosarcoma: long-term outcome and risk of late recurrence","volume":"453","author":"Rose","year":"2006","journal-title":"Clin Orthop Relat Res"},{"key":"2023092723195024700_ref78","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.ejca.2005.04.052","article-title":"Periosteal osteosarcoma\u2014a European review of outcome","volume":"41","author":"Grimer","year":"2005","journal-title":"Eur J Cancer"},{"key":"2023092723195024700_ref79","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/1097-0142(19900315)65:6<1418::AID-CNCR2820650629>3.0.CO;2-Q","article-title":"Low-grade intraosseous osteosarcoma","volume":"65","author":"Kurt","year":"1990","journal-title":"Cancer"},{"key":"2023092723195024700_ref80","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2106\/00004623-198466010-00008","article-title":"Dedifferentiated parosteal osteosarcoma","volume":"66","author":"Wold","year":"1984","journal-title":"J Bone Joint Surg Am"},{"key":"2023092723195024700_ref81","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/cncr.21039","article-title":"Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute","volume":"103","author":"Bertoni","year":"2005","journal-title":"Cancer"},{"key":"2023092723195024700_ref82","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM198606193142502","article-title":"The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity","volume":"314","author":"Link","year":"1986","journal-title":"N Engl J Med"},{"key":"2023092723195024700_ref83","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E","article-title":"Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy","volume":"49","author":"Rosen","year":"1982","journal-title":"Cancer"},{"key":"2023092723195024700_ref84","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JCO.1992.10.1.5","article-title":"Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience","volume":"10","author":"Meyers","year":"1992","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref85","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2018.11.027","article-title":"Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort","volume":"109","author":"Smeland","year":"2019","journal-title":"Eur J Cancer"},{"key":"2023092723195024700_ref86","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival\u2014a report from the Children\u2019s Oncology Group","volume":"26","author":"Meyers","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref87","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1023\/A:1008391103132","article-title":"Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group\u2019s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs","volume":"9","author":"Fuchs","year":"1998","journal-title":"Ann Oncol"},{"key":"2023092723195024700_ref88","doi-asserted-by":"crossref","first-page":"106133","DOI":"10.1016\/j.oraloncology.2022.106133","article-title":"Does neoadjuvant chemotherapy provide a survival benefit in maxillofacial osteosarcoma: a systematic review and pooled analysis","volume":"135","author":"Khadembaschi","year":"2022","journal-title":"Oral Oncol"},{"key":"2023092723195024700_ref89","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.oraloncology.2007.03.001","article-title":"Craniofacial osteosarcoma experience of the cooperative German-Austrian-Swiss osteosarcoma study group","volume":"44","author":"Jasnau","year":"2008","journal-title":"Oral Oncol"},{"key":"2023092723195024700_ref90","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bjoms.2010.02.012","article-title":"Sarcomas of the head and neck: a 10-year retrospective of 25 patients to evaluate treatment modalities, function and survival","volume":"49","author":"Ketabchi","year":"2011","journal-title":"Br J Oral Maxillofac Surg"},{"key":"2023092723195024700_ref91","first-page":"547","article-title":"Osteosarcoma: a meta-analysis and review of the literature","volume":"44","author":"Friebele","year":"2015","journal-title":"Am J Orthop (Belle Mead NJ)"},{"key":"2023092723195024700_ref92","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.joms.2010.10.023","article-title":"Osteosarcoma of the jaws: factors influencing prognosis","volume":"69","author":"Granowski-LeCornu","year":"2011","journal-title":"J Oral Maxillofac Surg"},{"key":"2023092723195024700_ref93","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/hed.21850","article-title":"Osteosarcoma of the jaw in children and young adults","volume":"34","author":"Huh","year":"2012","journal-title":"Head Neck"},{"key":"2023092723195024700_ref94","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/annonc\/mds507","article-title":"Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC\/REFCOR and SFCE","volume":"24","author":"Thariat","year":"2013","journal-title":"Ann Oncol"},{"key":"2023092723195024700_ref95","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/hed.24556","article-title":"Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults","volume":"39","author":"Boon","year":"2017","journal-title":"Head Neck"},{"key":"2023092723195024700_ref96","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2310\/7070.2004.03013","article-title":"Osteogenic sarcoma of the mandible and maxilla: a Canadian review (1980\u20132000)","volume":"33","author":"Canadian Society of Otolaryngology\u2013Head and Neck Surgery Oncology Study Group","year":"2004","journal-title":"J Otolaryngol"},{"issue":"Suppl. 4","key":"2023092723195024700_ref97","doi-asserted-by":"crossref","first-page":"iv79","DOI":"10.1093\/annonc\/mdy310","article-title":"Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"2023092723195024700_ref98","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1200\/JCO.2002.08.081","article-title":"High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study","volume":"20","author":"Fagioli","year":"2002","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref99","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1002\/cncr.24368","article-title":"Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients","volume":"115","author":"Berger","year":"2009","journal-title":"Cancer"},{"key":"2023092723195024700_ref100","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2003.08.132","article-title":"Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols","volume":"21","author":"Kager","year":"2003","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref101","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.2005.04.063","article-title":"Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)","volume":"23","author":"Kempf-Bielack","year":"2005","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref102","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/ijc.32180","article-title":"Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma","volume":"145","author":"Wang","year":"2019","journal-title":"Int J Cancer"},{"key":"2023092723195024700_ref103","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3389\/fonc.2020.01642","article-title":"Receptor tyrosine kinase in osteosarcoma treatment: which is the key target","volume":"10","author":"Tian","year":"2020","journal-title":"Front Oncol"},{"key":"2023092723195024700_ref104","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol"},{"key":"2023092723195024700_ref105","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1200\/JCO.18.02374","article-title":"Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma","volume":"37","author":"Davis","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref106","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1634\/theoncologist.2018-0542","article-title":"Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial","volume":"24","author":"Xie","year":"2019","journal-title":"Oncologist"},{"key":"2023092723195024700_ref107","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol"},{"key":"2023092723195024700_ref108","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/2159-8290.CD-17-1152","article-title":"Genome-informed targeted therapy for osteosarcoma","volume":"9","author":"Sayles","year":"2019","journal-title":"Cancer Discov"},{"key":"2023092723195024700_ref109","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/JCO.2003.03.006","article-title":"Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor","volume":"21","author":"Schleiermacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref110","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/(SICI)1097-0142(19960815)78:4<892::AID-CNCR29>3.0.CO;2-P","article-title":"Significance of surgical margin on the prognosis of patients with Ewing\u2019s sarcoma. A report from the Cooperative Ewing\u2019s Sarcoma Study","volume":"78","author":"Ozaki","year":"1996","journal-title":"Cancer"},{"key":"2023092723195024700_ref111","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0360-3016(02)03797-5","article-title":"Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials","volume":"55","author":"","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023092723195024700_ref112","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2172::AID-CNCR25>3.0.CO;2-7","article-title":"Bone sarcomas of the head and neck in children: the St Jude Children\u2019s Research Hospital experience","volume":"88","author":"Daw","year":"2000","journal-title":"Cancer"},{"key":"2023092723195024700_ref113","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/j.suronc.2010.01.006","article-title":"The role of surgery in children with head and neck rhabdomyosarcoma and Ewing\u2019s sarcoma","volume":"19","author":"Gradoni","year":"2010","journal-title":"Surg Oncol"},{"key":"2023092723195024700_ref114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/13577149977811","article-title":"Ewing\u2019s sarcoma of the head and neck: a retrospective analysis of 24 cases","volume":"3","author":"Allam","year":"1999","journal-title":"Sarcoma"},{"key":"2023092723195024700_ref115","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1200\/JCO.1990.8.9.1514","article-title":"Multimodal therapy for the management of nonpelvic, localized Ewing\u2019s sarcoma of bone: intergroup study IESS-II","volume":"8","author":"Burgert","year":"1990","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref116","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa020890","article-title":"Addition of ifosfamide and etoposide to standard chemotherapy for Ewing\u2019s sarcoma and primitive neuroectodermal tumor of bone","volume":"348","author":"Grier","year":"2003","journal-title":"N Engl J Med"},{"key":"2023092723195024700_ref117","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1200\/JCO.2008.19.1478","article-title":"Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children\u2019s Oncology Group Study","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref118","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","article-title":"Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children\u2019s Oncology Group","volume":"30","author":"Womer","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref119","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1200\/JCO.2001.19.6.1818","article-title":"Localized Ewing tumor of bone: final results of the cooperative Ewing\u2019s Sarcoma Study CESS 86","volume":"19","author":"Paulussen","year":"2001","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/1097-0142(19880101)61:1<23::AID-CNCR2820610106>3.0.CO;2-M","article-title":"A 6-year experience of a European cooperative trial","volume":"61","author":"Multidisciplinary treatment of primary Ewing\u2019s sarcoma of bone","year":"1988","journal-title":"Cancer"},{"key":"2023092723195024700_ref121","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1200\/JCO.2013.54.4833","article-title":"Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial","volume":"32","author":"Le Deley","year":"2014","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref122","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13063-019-4026-8","article-title":"International randomized controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumors \u2013 EURO EWING 2012 protocol","volume":"21","author":"Anderton","year":"2020","journal-title":"Trials"},{"key":"2023092723195024700_ref123","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(22)01790-1","article-title":"Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomized, phase 3 trial","volume":"400","author":"Brennan","year":"2022","journal-title":"Lancet"},{"key":"2023092723195024700_ref124","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/pbc.23040","article-title":"Risk of recurrence and survival after relapse in patients with Ewing sarcoma","volume":"57","author":"Stahl","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"2023092723195024700_ref125","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/bmt.2009.184","article-title":"Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases","volume":"45","author":"Burdach","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"2023092723195024700_ref126","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(10)70023-1","article-title":"Angiosarcoma","volume":"11","author":"Young","year":"2010","journal-title":"Lancet Oncol"},{"key":"2023092723195024700_ref127","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hed.21513","article-title":"Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp","volume":"33","author":"Guadagnolo","year":"2011","journal-title":"Head Neck"},{"key":"2023092723195024700_ref128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamaoto.2014.3584","article-title":"Angiosarcoma of the scalp and face: the Mayo Clinic experience","volume":"141","author":"Patel","year":"2015","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2023092723195024700_ref129","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/bjd.13110","article-title":"Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study","volume":"171","author":"Fujisawa","year":"2014","journal-title":"Br J Dermatol"},{"key":"2023092723195024700_ref130","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study","volume":"26","author":"Penel","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref131","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","article-title":"Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-soft tissue and bone sarcoma group (EORTC study 62043)","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref132","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1002\/cncr.30926","article-title":"Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma","volume":"123","year":"2017","journal-title":"Cancer"},{"key":"2023092723195024700_ref133","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(18)30676-4","article-title":"Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial","volume":"20","author":"Martin-Broto","year":"2019","journal-title":"Lancet Oncol"},{"key":"2023092723195024700_ref134","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1634\/theoncologist.2017-0161","article-title":"Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma","volume":"23","author":"Stacchiotti","year":"2018","journal-title":"Oncologist"},{"key":"2023092723195024700_ref135","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jamaoncol.2018.4490","article-title":"Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma: a review","volume":"5","author":"Paoluzzi","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023092723195024700_ref136","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-015-2918-1","article-title":"Unique features of trabectedin mechanism of action","volume":"77","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023092723195024700_ref137","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/bjc.2014.149","article-title":"Trabectedin, a drug acting on both cancer cells and the tumour microenvironment","volume":"111","author":"D\u2019Incalci","year":"2014","journal-title":"Br J Cancer"},{"key":"2023092723195024700_ref138","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.annonc.2021.04.014","article-title":"A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial","volume":"32","author":"Le Cesne","year":"2021","journal-title":"Ann Oncol"},{"key":"2023092723195024700_ref139","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"Lancet Oncol"},{"key":"2023092723195024700_ref140","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(15)70098-7","article-title":"Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study","volume":"16","author":"Kawai","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023092723195024700_ref141","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ejca.2014.01.012","article-title":"Randomized phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas","volume":"50","author":"Blay","year":"2014","journal-title":"Eur J Cancer"},{"key":"2023092723195024700_ref142","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2023092723195024700_ref143","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomized, open-label, multicenter, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"key":"2023092723195024700_ref144","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.2016.71.6605","article-title":"Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine","volume":"35","author":"Demetri","year":"2017","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref145","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1118\/1.1380433","article-title":"A compact ridge filter for spread out Bragg peak production in pulsed proton clinical beams","volume":"28","author":"Kostjuchenko","year":"2001","journal-title":"Med Phys"},{"key":"2023092723195024700_ref146","doi-asserted-by":"crossref","first-page":"N301","DOI":"10.1088\/0031-9155\/48\/22\/N01","article-title":"Ridge filter design for proton therapy at Hyogo Ion Beam Medical Center","volume":"48","author":"Akagi","year":"2003","journal-title":"Phys Med Biol"},{"key":"2023092723195024700_ref147","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1088\/0031-9155\/57\/22\/7261","article-title":"Impact of enhancements in the local effect model (LEM) on the predicted RBE-weighted target dose distribution in carbon ion therapy","volume":"57","author":"Grun","year":"2012","journal-title":"Phys Med Biol"},{"key":"2023092723195024700_ref148","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1245\/s10434-010-0935-1","article-title":"Proton-beam, intensity-modulated, and\/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas","volume":"17","author":"Yoon","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"2023092723195024700_ref149","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.ijrobp.2008.12.019","article-title":"Carbon ion radiotherapy for unresectable retroperitoneal sarcomas","volume":"75","author":"Serizawa","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023092723195024700_ref150","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ijrobp.2016.02.012","article-title":"Carbon ion radiation therapy for unresectable sacral chordoma: an analysis of 188 cases","volume":"95","author":"Imai","year":"2016","journal-title":"Int J Radiat Oncol Bio Phys"},{"key":"2023092723195024700_ref151","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S1470-2045(14)70412-7","article-title":"Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience","volume":"16","author":"Kamada","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023092723195024700_ref152","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1200\/JCO.2014.56.1548","article-title":"Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma","volume":"32","author":"Ladra","year":"2014","journal-title":"J Clin Oncol"},{"key":"2023092723195024700_ref153","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ijrobp.2011.03.038","article-title":"Proton radiotherapy for pediatric Ewing\u2019s sarcoma: initial clinical outcomes","volume":"82","author":"Rombi","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023092723195024700_ref154","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/hed.25479","article-title":"Proton therapy for skull base tumors: a revies of clinical outcomes for chordomas and chondrosarcomas","volume":"41","author":"Mercado","year":"2019","journal-title":"Head Neck"},{"key":"2023092723195024700_ref155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/hed.20144","article-title":"Skull base chordoma","volume":"27","author":"Mendenhall","year":"2005","journal-title":"Head Neck"},{"key":"2023092723195024700_ref156","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/cas.13192","article-title":"Proton beam therapy for bone sarcomas of the skull base and spine: a retrospective nationwide multicenter study in Japan","volume":"108","author":"Yusuke","year":"2017","journal-title":"Cancer Sci"},{"key":"2023092723195024700_ref157","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13014-022-02089-0","article-title":"Efficacy and safety of carbon ion radiotherapy for bone sarcomas: a systemic revies and meta-analysis","volume":"17","author":"Dong","year":"2022","journal-title":"CRadiat Oncol"},{"key":"2023092723195024700_ref158","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13569-016-0060-4","article-title":"UK guidelines for the management of soft tissue sarcomas","volume":"6","author":"Dangoor","year":"2016","journal-title":"Clin Sarcoma Res"},{"key":"2023092723195024700_ref159","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1002\/cncr.27451","article-title":"Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk","volume":"118","author":"Akira","year":"2012","journal-title":"Cancer"},{"key":"2023092723195024700_ref160","doi-asserted-by":"crossref","first-page":"22976","DOI":"10.18632\/oncotarget.25165","article-title":"Carbon ion radiotherapy for inoperable pediatric osteosarcoma","volume":"9","author":"Osama","year":"2018","journal-title":"Oncotarget"},{"key":"2023092723195024700_ref161","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1002\/cncr.31298","article-title":"High control rate of proton- and carbon-ion-beam treatment with intensity-modulated active raster scanning in 101 patients with skull base chondrosarcoma at the Heidelberg Ion Beam Therapy Center","volume":"124","author":"Mattke","year":"2018","journal-title":"Cancer"},{"key":"2023092723195024700_ref162","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1227\/01.NEU.0000143330.30405.AA","article-title":"Radiotherapeutic factors in the management of cervical-basal chordomas and chondrosarcomas","volume":"55","author":"No\u00ebl","year":"2004","journal-title":"Neurosurgery"},{"key":"2023092723195024700_ref163","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2006.12.059","article-title":"Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas","volume":"68","author":"Schulz-Ertner","year":"2007","journal-title":"Int J Radiat Oncol Bio Phys"},{"key":"2023092723195024700_ref164","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.radonc.2016.05.011","article-title":"Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy","volume":"120","author":"Weber","year":"2016","journal-title":"Radiother Oncol"},{"key":"2023092723195024700_ref165","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.ijrobp.2008.12.055","article-title":"Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term reports","volume":"75","author":"Ares","year":"2009","journal-title":"Int J Radiat Oncol Bio Phys"},{"key":"2023092723195024700_ref166","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/neuonc\/noaa067","article-title":"Proton and carbon ion radiotherapy in skull base chordomas: a prospective study base on a dual particle and patient-customized treatment strategy","volume":"22","author":"Innalfi","year":"2020","journal-title":"Neuro Oncol"},{"key":"2023092723195024700_ref167","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S1470-2045(14)71190-8","article-title":"Building a global consensus approach to chordoma: a position paper from the medical and patient community","volume":"16","author":"Stecchiotti","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023092723195024700_ref168","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrclinonc.2009.183","article-title":"Charged particles in radiation oncology","volume":"7","author":"Durante","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2023092723195024700_ref169","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00066-022-02002-4","article-title":"Proton and carbon ion beam treatment with active raster scanning method in 147 patients with skull base chordoma ant the Heidelberg Ion Beam Therapy Center-a single-center experience","volume":"199","author":"Mattke","year":"2023","journal-title":"Strahlenther Onkol"},{"key":"2023092723195024700_ref170","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2407-10-96","article-title":"Non-randomized therapy trial to determine the safety an efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma","volume":"10","author":"Blattmann","year":"2010","journal-title":"BMC Cancer"},{"key":"2023092723195024700_ref171","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/1471-2407-10-606","article-title":"Randomized trial of proton vs. carbon ion radiation therapy in patients with low and intermediate grade chondrosarcoma of the skull base, clinical phase III study","volume":"10","author":"Nikoghosyan","year":"2010","journal-title":"BMC Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/9\/743\/51777980\/hyad048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/9\/743\/51777980\/hyad048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T23:33:24Z","timestamp":1695857604000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/9\/743\/7193787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,10]]},"references-count":171,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,6,10]]},"published-print":{"date-parts":[[2023,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad048","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,6,10]]}}}